Last reviewed · How we verify
Rocuronium dosing
Rocuronium is a neuromuscular blocking agent that competitively binds to acetylcholine receptors at the neuromuscular junction, preventing muscle contraction.
Rocuronium is a neuromuscular blocking agent that competitively binds to acetylcholine receptors at the neuromuscular junction, preventing muscle contraction. Used for Facilitation of endotracheal intubation during anesthesia induction, Maintenance of neuromuscular blockade during general anesthesia and mechanical ventilation.
At a glance
| Generic name | Rocuronium dosing |
|---|---|
| Sponsor | Clare Hayes-Bradley |
| Drug class | Neuromuscular blocking agent (non-depolarizing) |
| Target | Nicotinic acetylcholine receptor at the neuromuscular junction |
| Modality | Small molecule |
| Therapeutic area | Anesthesia |
| Phase | FDA-approved |
Mechanism of action
Rocuronium is a non-depolarizing (competitive) neuromuscular blocker that antagonizes acetylcholine at the motor endplate by occupying nicotinic acetylcholine receptors without activating them. This prevents depolarization and muscle contraction, producing paralysis. It is used during anesthesia to facilitate intubation and maintain muscle relaxation during surgery.
Approved indications
- Facilitation of endotracheal intubation during anesthesia induction
- Maintenance of neuromuscular blockade during general anesthesia and mechanical ventilation
Common side effects
- Prolonged neuromuscular blockade
- Histamine release (flushing, hypotension, tachycardia)
- Anaphylaxis
- Postoperative residual curarization
Key clinical trials
- Intubation Conditions Achieved With Rapid Co-administration of Rocuronium and Propofol Versus Classical Induction (PHASE4)
- Intraoperative Multimodal Monitoring as a Means in Reducing the Duration of Mechanical Ventilation in High-Risk Patients Undergoing Major Abdominal Procedures - A Pilot Study (NA)
- SEdation Versus General Anesthesia for Endovascular Therapy in Acute Ischemic Stroke (PHASE4)
- Developing a Physiology-Pharmacodynamic Model of Rocuronium Dose and Cardiac Output to Investigate the Onset Time of Neuromuscular Relaxation (PHASE4)
- Oliceridine Dose for Tracheal Intubation Hemodynamic Elevation: Up-and-Down Trial (NA)
- Evaluation Of The Influence Of Anesthetic Interventions On The Evolution Of Hepatic Neoplastic Processes (NA)
- Remimazolam Infusion in Kidney Transplant Patients: A Multicenter Study (PHASE1)
- Delayed Against Rapid Sequence Induction in Adults With Medical Diseases Undergoing Emergency Endotracheal Intubation. (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Rocuronium dosing CI brief — competitive landscape report
- Rocuronium dosing updates RSS · CI watch RSS
- Clare Hayes-Bradley portfolio CI